



AF/16477

TRANSMITTAL OF APPEAL BRIEFDocket No.
JJJ-P01-514

In re Application of: Cohen et al.

Application No. 09/445,328	Filing Date December 7, 1999	Examiner D. S. Romeo	Group Art Unit 1647
-------------------------------	---------------------------------	-------------------------	------------------------

Invention: THERAPIES FOR ACUTE RENAL FAILURE

TO THE COMMISSIONER OF PATENTS:

Transmitted herewith is the Appeal Brief in this application, with respect to the Notice of Appeal filed: December 8, 2006

The fee for filing this Appeal Brief is \$ 500.00

Large Entity Small Entity

A petition for extension of time is also enclosed.

The fee for the extension of time is _____

A check in the amount of _____ is enclosed.

Charge the amount of the fee to Deposit Account No. 18-1945
This sheet is submitted in duplicate.

Payment by credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any additional fees that may be required or
credit any overpayment to Deposit Account No. 18-1945
This sheet is submitted in duplicate.

Ignacio Perez De La Cruz

Attorney Reg. No. : 55,535

FISH & NEAVE IP GROUP, ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

Dated: February 9, 2007

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Appeal Brief - Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 9, 2007

Signature:

(Dawn Class)



Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT	(\$)	500.00
--------------------------------	------	--------

Complete if Known	
Application Number	09/445,328
Filing Date	December 7, 1999
First Named Inventor	Charles M. Cohen
Examiner Name	D. S. Romeo
Art Unit	1647
Attorney Docket No.	JJJ-P01-514

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____
 Deposit Account Deposit Account Number: 18-1945 Deposit Account Name: Fish & Neave IP Group, Ropes & Gray LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee
 Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 Credit any overpayments

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

<u>Application Type</u>	<u>FILING FEES</u>		<u>SEARCH FEES</u>		<u>EXAMINATION FEES</u>		<u>Fees Paid (\$)</u>
	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEESFee Description

Each claim over 20 (including Reissues)

<u>Small Entity</u>	<u>Fee (\$)</u>
---------------------	-----------------

50 25

Each independent claim over 3 (including Reissues)

200 100

Multiple dependent claims

360 180

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
---------------------	---------------------	-----------------	----------------------

Multiple Dependent Claims

<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
-----------------	----------------------

<u>Indep. Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
----------------------	---------------------	-----------------	----------------------

<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
-----------------	----------------------

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
---------------------	---------------------	---	-----------------	----------------------

- 100 = _____ /50 _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 1402 Filing a brief in support of an appeal

500.00

SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	55,535
Name (Print/Type)	Ignacio Perez De La Cruz	Date	February 9, 2007

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Appeal Brief - Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 9, 2007

Signature:

(Dawn Class)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Appeal Brief - Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 9, 2007

Signature:

(Dawn Class)

Docket No.: JJJ-P01-514
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Sampath et al.

Application No.: 09/445,328

Confirmation No.: 9813

Filed: December 7, 1999

Art Unit: 1647

For: THERAPIES FOR ACUTE RENAL FAILURE

Examiner: D. S. Romeo

APPEAL BRIEF

MS Appeal Brief - Patents
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

A Notice of Appeal was filed on December 8, 2006 and was received by the USPTO on December 11, 2006. The deadline for filing an Appeal Brief is two months from the date of receipt, or February 11, 2007. Accordingly, this Appeal Brief is timely filed and is in furtherance of the Notice of Appeal.

Payment of fees required under § 41.20(b)(2) is authorized in the accompanying TRANSMITTAL OF APPEAL BRIEF.

This brief contains items under the following headings as required by 37 C.F.R. § 41.37:

- I. Real Party In Interest
 - II. Related Appeals and Interferences
 - III. Status of Claims
 - IV. Status of Amendments
 - V. Summary of Claimed Subject Matter
 - VI. Grounds of Rejection to be Reviewed on Appeal
 - VII. Groupings of the Claims

Application No. 09/445,328
Appeal Brief dated February 9, 2007
After Notice of Appeal dated December 8, 2006

Docket No.: JJJ-P01-514

- VIII. Argument
- IX Claims Appendix
- X. Evidence Appendix
- XI. Related Proceedings Appendix
- XII. Conclusions
- XIII. Exhibit A

I. REAL PARTY IN INTEREST

The real parties in interest for this appeal are as follows:

Curis, Inc., the owner of the application, and Johnson & Johnson, the licensee of the application.

II. RELATED APPEALS, INTERFERENCES, AND JUDICIAL PROCEEDINGS

To the best of the knowledge of the undersigned, there are no other appeals, interferences or judicial proceedings known to the Appellant, the Appellant's legal representative, or the above-noted real party of interest that will directly affect or be directly affected by, or have a bearing on, the Board's decision in this appeal.

III. STATUS OF CLAIMS

A. Total Number of Claims in Application

There are 45 claims pending in application.

B. Current Status of Claims

1. Claims canceled: 1, 3, 4, 7, 10, 13, 39-52
2. Claims withdrawn from consideration but not canceled: 21, 22, 25, and 28-34
3. Claims pending: 2, 5, 6, 8, 9, 11, 12, 14-20, 23, 24, 26, 27, 35-38, and 53-65
4. Claims allowed: None
5. Claims objected: None
6. Claims rejected: 2, 5, 6, 8, 9, 11, 12, 14-38, and 53-65

C. Claims On Appeal

The claims on appeal are claims 2, 5, 6, 8, 9, 11, 12, 14-38, and 53-65.

IV. STATUS OF AMENDMENTS

An amendment was filed on December 8, 2006 in response to the Final Office Action dated September 21, 2006. The Examiner entered the amendment as indicated in the Advisory Action dated January 18, 2007.

V. SUMMARY OF CLAIMED SUBJECT MATTER

Applicants provide the following concise summary of the subject matter defined in each of the independent claims involved in the appeal, with appropriate page and line numbers referring to the cited portions of the originally-filed specification:

Claim 2

The methods and compositions of this invention capitalize in part upon the discovery that certain proteins of eukaryotic origin, defined herein as OP/BMP renal therapeutic agents, and including members of the osteogenic protein/bone morphogenetic protein (OP/BMP) family of proteins, may be used in the treatment of subjects in, or at risk of, acute renal failure. (page 2, line 33-36). Useful renal therapeutic agents include polypeptides, or functional variants of polypeptides, comprising at least the C-terminal six-or seven-cysteine domain of a mammalian protein selected from the group consisting of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, and proteins which exhibit at least 70% or, more preferably, 75% or 80% amino acid sequence homology with the amino acid sequence of the seven-cysteine domain of human OP-1; and are (a) capable of inducing chondrogenesis in the Reddi-Sampath ectopic bone assay (Sampath and Reddi (1981), Proc. Natl. Acad. Sci. (USA) 78:7599-7603) or a substantially equivalent assay, (b) capable of significantly preventing, inhibiting, delaying or alleviating the permanent or progressive loss of renal function which may result from acute renal failure in a standard animal model of acute renal failure, or (c) capable of causing a clinically significant improvement in a standard marker of renal function when administered to a mammal in, or at risk of, acute renal failure.

(page 2, line 36 to page 3, line 10). The renal therapeutic agents of the present invention may be evaluated for their therapeutic efficiency in causing a clinically significant improvement in a standard marker of renal function when administered to a mammalian subject. (page 11, lines 5-7).

Claim 53

The methods and compositions of this invention capitalize in part upon the discovery that certain proteins of eukaryotic origin, defined herein as OP/BMP renal therapeutic agents, and including members of the osteogenic protein/bone morphogenetic protein (OP/BMP) family of proteins, may be used in the treatment of subjects in, or at risk of, acute renal failure. (page 2, line 33-36). The renal therapeutic agents useful herein include therapeutically effective proteins in which the amino acid sequences comprise a sequence sharing at least 60% amino acid sequence identity, and preferably, 65% or 70% identity with the C-terminal seven cysteine domain present in the active forms of human OP-1. (page 9, lines 9-13). The renal therapeutic agents of the present invention may be evaluated for their therapeutic efficiency in causing a clinically significant improvement in a standard marker of renal function when administered to a mammalian subject. (page 11, lines 5-7)

Claim 58

The methods and compositions of this invention capitalize in part upon the discovery that certain proteins of eukaryotic origin, defined herein as OP/BMP renal therapeutic agents, and including members of the osteogenic protein/bone morphogenetic protein (OP/BMP) family of proteins, may be used in the treatment of subjects in, or at risk of, acute renal failure. (page 2, line 33-36). The renal therapeutic agents useful herein include therapeutically effective proteins in which the amino acid sequences comprise a sequence sharing at least 60% amino acid sequence identity, and preferably, 65% or 70% identity with the C-terminal seven

cysteine domain present in the active forms of human OP-1. (page 9, lines 9-13). Useful renal therapeutic agents include polypeptides, or functional variants of polypeptides, comprising at least the C-terminal six-or seven-cysteine domain of a mammalian protein selected from the group consisting of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, and proteins which exhibit at least 70% or, more preferably, 75% or 80% amino acid sequence homology with the amino acid sequence of the seven-cysteine domain of human OP-1; and are (a) capable of inducing chondrogenesis in the Reddi-Sampath ectopic bone assay (Sampath and Reddi (1981), Proc. Natl. Acad. Sci. (USA) 78:7599-7603) or a substantially equivalent assay, (b) capable of significantly preventing, inhibiting, delaying or alleviating the permanent or progressive loss of renal function which may result from acute renal failure in a standard animal model of acute renal failure, or (c) capable of causing a clinically significant improvement in a standard marker of renal function when administered to a mammal in, or at risk of, acute renal failure. (page 2, line 36 to page 3, line 10). The renal therapeutic agents of the present invention may be evaluated for their therapeutic efficiency in causing a clinically significant improvement in a standard marker of renal function when administered to a mammalian subject. (page 11, lines 5-7). Generally speaking, acute renal failure may be due to pre-renal, post-renal, or intrinsic renal causes. (Page 1, lines 20-21). As used herein, pre-renal causes of acute renal failure include decreased cardiac output, hypovolemia, volume redistribution, and altered vascular resistance. (page 4, lines 29-31).

Claim 61

The methods and compositions of this invention capitalize in part upon the discovery that certain proteins of eukaryotic origin, defined herein as OP/BMP renal therapeutic agents, and including members of the osteogenic protein/bone morphogenetic protein (OP/BMP) family of proteins, may be used in the treatment of subjects in, or at risk of, acute renal failure. (page 2, line 33-36). The renal

therapeutic agents useful herein include therapeutically effective proteins in which the amino acid sequences comprise a sequence sharing at least 60% amino acid sequence identity, and preferably, 65% or 70% identity with the C-terminal seven cysteine domain present in the active forms of human OP-1. (page 9, lines 9-13). Useful renal therapeutic agents include polypeptides, or functional variants of polypeptides, comprising at least the C-terminal six-or seven-cysteine domain of a mammalian protein selected from the group consisting of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, and proteins which exhibit at least 70% or, more preferably, 75% or 80% amino acid sequence homology with the amino acid sequence of the seven-cysteine domain of human OP-1; and are (a) capable of inducing chondrogenesis in the Reddi-Sampath ectopic bone assay (Sampath and Reddi (1981), Proc. Natl. Acad. Sci. (USA) 78:7599-7603) or a substantially equivalent assay, (b) capable of significantly preventing, inhibiting, delaying or alleviating the permanent or progressive loss of renal function which may result from acute renal failure in a standard animal model of acute renal failure, or (c) capable of causing a clinically significant improvement in a standard marker of renal function when administered to a mammal in, or at risk of, acute renal failure. (page 2, line 36 to page 3, line 10). The renal therapeutic agents of the present invention may be evaluated for their therapeutic efficiency in causing a clinically significant improvement in a standard marker of renal function when administered to a mammalian subject. (page 11, lines 5-7). Generally speaking, acute renal failure may be due to pre-renal, post-renal, or intrinsic renal causes. (Page 1, lines 20-21). As used herein, pre-renal causes of acute renal failure include decreased cardiac output, hypovolemia, volume redistribution, and altered vascular resistance. (page 4, lines 29-31). Administration is expected to be continuous or frequent (e.g., daily) during the period of acute renal failure, typically 1-3 weeks, but may also be continued for several weeks or months after the acute phase. (page 3, lines 15-17).

Claim 64

The methods and compositions of this invention capitalize in part upon the discovery that certain proteins of eukaryotic origin, defined herein as OP/BMP renal therapeutic agents, and including members of the osteogenic protein/bone morphogenetic protein (OP/BMP) family of proteins, may be used in the treatment of subjects in, or at risk of, acute renal failure. (page 2, line 33-36). The renal therapeutic agents useful herein include therapeutically effective proteins in which the amino acid sequences comprise a sequence sharing at least 60% amino acid sequence identity, and preferably, 65% or 70% identity with the C-terminal seven cysteine domain present in the active forms of human OP-1. (page 9, lines 9-13). Useful renal therapeutic agents include polypeptides, or functional variants of polypeptides, comprising at least the C-terminal six-or seven-cysteine domain of a mammalian protein selected from the group consisting of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, and proteins which exhibit at least 70% or, more preferably, 75% or 80% amino acid sequence homology with the amino acid sequence of the seven-cysteine domain of human OP-1; and are (a) capable of inducing chondrogenesis in the Reddi-Sampath ectopic bone assay (Sampath and Reddi (1981), Proc. Natl. Acad. Sci. (USA) 78:7599-7603) or a substantially equivalent assay, (b) capable of significantly preventing, inhibiting, delaying or alleviating the permanent or progressive loss of renal function which may result from acute renal failure in a standard animal model of acute renal failure, or (c) capable of causing a clinically significant improvement in a standard marker of renal function when administered to a mammal in, or at risk of, acute renal failure. (page 2, line 36 to page 3, line 10). The renal therapeutic agents of the present invention may be evaluated for their therapeutic efficiency in causing a clinically significant improvement in a standard marker of renal function when administered to a mammalian subject. (page 11, lines 5-7). Generally speaking, acute renal failure may be due to pre-renal, post-renal, or intrinsic renal causes. (Page 1, lines 20-21). As used herein, pre-renal causes of acute renal failure

include decreased cardiac output, hypovolemia, volume redistribution, and altered vascular resistance. (page 4, lines 29-31). In some cases, however, the subjects may present with other symptoms (e.g. osteodystrophy) for which renal therapeutic agent treatment would be indicated. (page 12, lines 5-6).

Although those teachings are summarized above, the Board is strongly urged to study the specification before considering the rejections on appeal.

VI. GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL

The single ground of rejection to be reviewed on appeal is whether independent claims 2, 53, 58, 61 and 64 satisfy the nonobviousness requirement of 35 U.S.C. 103(a).

Claims 2 and 53 are rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Kelly (J Clin Invest. 1996 Feb 15;97(4):1056-63) in view of Kubersampath (WO 93/04692) and Lefer (J Mol Cell Cardiol. 1992 Jun; 24(6):585-93).

Claim 58, 61 and 64 are rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Kelly (J Clin Invest. 1996 Feb 15;97(4):1056-63) in view of Kubersampath (WO 93/04692), Lefer (J Mol Cell Cardiol. 1992 Jun;24(6):585-93), Anderson (Chapter 275, in Harrison's Principles of Internal Medicine, 1980) and Brady (Chapter 236, in Harrison's Principles of Internal Medicine, 1994).

VII. GROUPING OF THE CLAIMS

Claims 2, 53, 58, 61, and 64 are the subject of this appeal.

Claims 8, 9, 55, and 56 depend directly from claim 2 and stand and fall together with this claim.

Claims 11, 12, 54, and 57 depend directly from claim 53 and stand and fall together with this claim.

Claims 5, 6, and 14-38 depend, direct or indirectly, from "claim 2 or 53" and stand and fall together with these claims.

Claims 59, 60, 62, 63, and 65 depend from claim 58 and stand and fall together with this claim.

For the convenience of the Board, the Table A below is provided indicating the relationship between the elements of the five independent claims (claims 2, 53, 58, 61, and 64) under appeal.

Table A: Comparison of Claim Elements of Claims under Appeal				
Claims	Agent	Cause of Acute Renal Failure	Agent Administration	Subjects being Treated
2	70% homologous to OP-1 Seven-Cys Domain	ANY	ANY	ANY
53	60% identical to OP-1 Seven-Cys Domain	ANY	ANY	ANY
58	70% homologous <u>OR</u> 60% identical to OP-1 Seven-Cys Domain	Pre-Renal	ANY	ANY
61	70% homologous <u>OR</u> 60% identical to OP-1 Seven-Cys Domain	Pre-Renal	Continuously for 1-3 weeks	ANY
64	70% homologous <u>OR</u> 60% identical to OP-1 Seven-Cys Domain	Pre-Renal	ANY	Afflicted with Osteodystrophy

Appellants note that a pre-renal cause of acute renal failure was elected as the species for search purposes. While claims 2 and 53 relate to any form of acute renal failure, claim 58 recites pre-renal causes of acute renal failure. As a result, Appellants have grouped claims 2, 53 and 58 for the appeal as standing and falling together. To simplify this appeal, appellants select claim 58 from this group of three claims to be argued in this appeal.

Claims 61 and 64 will be argued separately since they recite at least one element not found in any one of claims 2, 53, or 58. Nevertheless, if the Board agrees with Appellants that claim 58 is nonobvious over the cited references, then claims 61 and 64 should also be deemed nonobvious since they incorporate all the elements found in claim 58.

VIII. ARGUMENT

CLAIM 58

The Examiner rejects claim 58 as being allegedly obvious over Kelly (J Clin Invest. 1996 Feb 15;97(4):1056-63) ("Kelly") in view of Kubersampath (WO 93/04692) ("Kubersampath") and Lefer (J Mol Cell Cardiol. 1992 Jun; 24(6):585-93) ("Lefer"). Claims that depend from claim 58 are rejected in further view of Anderson (Chapter 275, in Harrison's Principles of Internal Medicine, 1980) ("Anderson") and Brady (Chapter 236, in Harrison's Principles of Internal Medicine, 1994) ("Brady").

The Examiner's argument for rejecting claim 58 may be outlined as follows:

(1) Kelly suggests that agents that block ICAM-adhesiveness or that block polymorphonuclear cell (PMC) activity might be effective in treating acute renal failure.

(2) Kubersampath teaches that the morphogen OP-1 is an anti-inflammatory agent that blocks ICAM adhesiveness.

(3) Lefer teaches that OP-1 is an anti-inflammatory agent that inhibits PMC activity.

(4) Therefore, one skilled in the art would expect that the anti-inflammatory OP-1 would be successful in treating acute renal failure.

The Examiner, then, assumes that if agent X is known to reduce inflammation, then one skilled in the art would reasonably expect that agent X would be effective in treating acute renal failure. Based on this central assumption, the Office Action concludes that since OP-1 is allegedly effective in treating inflammation then one skilled in the art would reasonably expect OP-1 to be effective in treating acute renal failure.

As will be shown below, this argument fails because at the time the subject application was filed, anti-inflammatory agents were known to *decrease* renal function, or even to cause outright renal failure, when administered to subjects. In particular, Transforming Growth Factor Beta 1(TGF β 1), Cyclosporin A (CsA) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) were documented in the scientific and medical literature to *decrease* renal function when administered to a subject. This clearly teaches away from use of anti-inflammatories in the

treatment of acute renal failure. Accordingly, one skilled on the art would have expected that administration of the anti-inflammatory OP-1 to a mammal afflicted with acute renal failure would have aggravated, not improved, renal function in the mammal. In other words, one skilled in the art would not have had a reasonable expectation that OP-1, or other morphogens, would be effective in treating acute renal failure.

(1) A Reasonable Expectation of Success is Lacking for the Use of OP-1 to Improve Renal Function in Subjects Afflicted with Acute Renal Failure

MPEP 706.02(j) sets forth three basic criteria needed to establish a *prima facie* case of obviousness: 1) the prior art references must teach or suggest all the claim limitations; 2) some motivation or suggestion, either found in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to combine or modify the references must be present; and 3) a reasonable expectation of success.

At least the third prong is not satisfied in this case. The Examiner has failed to show why one skilled in the art would have ignored the scientific literature documenting the adverse renal effects of anti-inflammatory agents, and why he would have selected the anti-inflammatory agent OP-1 to improve renal function in a subject with renal dysfunction (i.e. with acute renal failure). In fact, one skilled in the art would have expected that the morphogen OP-1 would not only fail to improve renal function in a subject afflicted with acute renal failure, but also that it would aggravate the renal dysfunction. The skilled artisan would not have expected OP-1 to be the exception among anti-inflammatory agents.

(2) Anti-Inflammatory Drugs were Known to be Detrimental to Renal Function

At the time the application was filed, it was well-documented in the scientific literature that anti-inflammatory agents reduced, rather than improved, renal function.

On pages 10-16 of the Amendment filed on November 12, 2004, Applicants established that Transforming Growth Factor Beta 1(TGF β 1), Cyclosporin A (CsA) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) were known at the time the subject application was filed to be both (i) anti-inflammatory agents which inhibit ICAM adhesiveness, and (ii) *detrimental* to renal

function. The November 12, 2004 amendment included thirteen scientific publications, as Exhibits A-M, documenting the anti-inflammatory and the renal-adverse side effects of these three agents. Rather than reproducing this section of the previous office action in this appeal brief, Appellants provide a summary of the documented adverse renal effects of these three agents in Table B below. The Board is nevertheless encouraged to review the arguments and the Exhibits as provided in the November 12, 2004 amendment in their entirety.

Table B. Documented adverse kidney effects of anti-inflammatory agents		
Agent	Exhibit #	Finding
TGFβ1	D	"Recent studies show that TGF-beta overexpression in experimental and human kidney diseases leads to progressive glomerular and tubulointerstitial scarring and renal failure," (Abstract) "New therapies may prevent progressive fibrosis in chronic kidney disease by suppressing the action of TGF-beta." (Abstract)
	F	"Overproduction of TGF-beta is the cause of pathologic matrix accumulation in the nephritic glomeruli" (Abstract) "Studies of humans with glomerulonephritis and diabetic nephropathy also strongly implicated TGF-beta in the pathogenesis of glomerular matrix build-up" (Abstract)
CsA	I	"Cyclosporine A causes an acute reduction in GFR." (Abstract) (GFR stands for Glomerular Filtration Rate, a primary measure of renal function
NSAIDs	K	"Approximately 1-5% of people who are exposed to a nonsteroidal anti-inflammatory drug (NSAID) will manifest one of a variety of renal function abnormalities ... Renal abnormalities include fluid and electrolyte disturbances, acute deterioration of renal function, nephritic syndrome with interstitial nephritis, and papillary necrosis" (Page 588, columns 1-2) "from the clinical point of view, the most worrisome renal side effect of NSAIDs is hemodynamically mediated acute renal failure, which occurs in individuals with pre-existing reduced renal blood perfusion" (Page 588, column 2)
	L	"Patients with pre-existing risk factors are susceptible to potentially life-threatening toxicities [from NSAIDs], including acute renal failure (ARF) and serious fluid and electrolyte disorders" (page S-61, column 1)
	M	"Among persons with normal renal function, who have no other risk factors (dehydration) for an acute hemodynamic effect, there is no risk. However, NSAID administration to susceptible persons may cause decrements in renal plasma flow and glomerular filtration rate within hours" (Abstract)

(3) One skilled in the Art Would Have Expected that Administration of OP-1 to a Mammal Afflicted with Acute Renal Failure Would Reduce, not Increase, Renal Function

OP-1 shares two key properties with TFG β 1, CsA and NSAIDs: (i) it decreases ICAM adhesiveness and (ii) it decreases PMC activity. OP-1 and TFG β 1 are also members of the TFG β superfamily of growth factors. The Examiner has focused exclusively on OP-1's anti-inflammatory property as the key attribute in making it a seemingly successful candidate for treating Acute Renal Failure (ARF).

But at the time the application was filed, anti-inflammatory agents were documented to actually cause renal dysfunction, especially in subjects with already impaired renal function. One skilled in the art would have expected that OP-1, just like its counterpart anti-inflammatory agents TFG β 1, CsA and NSAIDs, would further impair renal function in a subject afflicted with acute renal failure. One skilled in the art would have expected that administration of the anti-inflammatory OP-1 polypeptide, based on its anti-inflammatory and neutrophil adhesion-inhibiting properties that it shares with NSAIDs, would reduce, rather than increase, renal function. If anything, the documented anti-renal effects of anti-inflammatory agents taught away from administering anti-inflammatory agents, such as OP-1, to subjects with impaired renal function.

While having the burden of proof, the Examiner has failed to establish why one skilled in the art would have made OP-1 the exception amongst anti-inflammatory agents. He has failed to show why one would have expected OP-1 to be the anomaly and to actually improve renal function where other anti-inflammatory agents failed. The burden of going forward was and is on the Examiner to overcome the presumption of lack of reasonable expectation of success legitimately established by applicant using documentary evidence during prosecution. Because he has failed to do so, he has failed to establish a *prima facie* case of obviousness in accordance with MPEP 706.02(j).

(4) The Examiner's Counterarguments Fail to Address Why OP-1 Would Have Been Expected to Be the Exception Among Anti-inflammatory Agents

In response to Appellants arguments, the Examiner alleges that there is no evidence of

record that OP-1 possesses any of the renal side effects of TGF β 1, CsA or NSAIDS. The Examiner claims that applicants have not met a burden of proof in providing a nexus between (i) anti-inflammatory agents inhibiting ICAM adhesiveness and (ii) anti-inflammatory agents being detrimental to acute renal function. But the burden is on the Examiner, not on applicants, to establish the third prong of the *prima facie* case of obviousness. It is the Examiner who must present evidence why one skilled on the art would have expected a fourth anti-inflammatory agent (OP-1) to be the exception among anti-inflammatories – to show why a fourth anti-inflammatory would be effective in treating acute renal failure when the three others anti-inflammatory agents impair renal function. The Examiner wants Appellants to provide evidence that OP-1 had the adverse renal effects of the other anti-inflammatory agents. But this is impossible because Appellants discovered that, contrary to expectation, OP-1 could improve renal function.

The Examiner has made some additional rebuttals on previous Office Actions, but none of them address the heart of the matter: why would OP-1 be the exception among anti-inflammatory agents? Some of these rebutting arguments are as follows:

(i) The Examiner alleges that despite the evidence showing the ineffectiveness of anti-inflammatories in treating ARF, one could not have known for sure whether OP-1 would fail in treating ARF until it was actually tested. The Examiner's position turns the test for obviousness on its head. The standard is the reasonable expectation that the invention would work successfully, and not whether there was the infinitesimal chance that OP-1 might improve renal function contrary to expectation. Indeed, since there is no evidence supplied by the Examiner that OP-1 would be effective in treating ARF, and documentary evidence shows that other anti-inflammatories were ineffective, there is no *prima facie* case of obviousness.

(ii) The Examiner points to differences between OP-1 and TGF β 1 in bone formation to suggest that the two molecules might have different biological properties in treating other organs. The question, however, is not whether the possibility exists, no matter how small, that two compounds can have different properties. The question is what properties one skilled in the art would have expected the morphogens to have and why one would have expected OP-1 to be an exception. Merely pointing out that OP-1 is a different compound than TGF β 1, CsA or an

NSAID, proves nothing. TGF β 1, CsA or an NSAID all have different structures from each other yet they all reduce inflammation and reduce renal function. The common teaching of such prior art is that anti-inflammatories generally have an adverse effect on renal function. The claimed invention runs counter to conventional wisdom.

(iii) The Examiner seeks to prematurely shift the burden of proof to Applicants, when the Examiner's own initial burden of proof has not yet been satisfied. Specifically, the Examiner is requiring applicants to prove that OP-1 would not be expected to exhibit the harmful renal effects of other anti-inflammatory agents, when it is the Examiner who bears the initial burden of showing why OP-1 should be considered as the exception amongst anti-inflammatory agents. MPEP 2142 imposes the initial burden on the examiner, and this burden has not been met.

CLAIM 61

As indicated in the preceding section, a reasonable expectation of success has not been established for claim 58. Claim 61 is identical to claim 58 except that it further recites "wherein the agent is administered continuously during the period of acute renal failure" and "wherein the period of acute renal failure lasts from one to three weeks." Therefore, the failure to establish a reasonable expectation of success for the method of claim 58 also applies to the method of claim 61, thus rendering claim 61 nonobvious.

A failure to establish a *prima facie* case of obviousness for claim 61 also arises from the failure of the Examiner to establish a basis as to how the combination of cited references teaches or suggests all the elements of claim 61. In particular, the Examiner has not shown how the combination of cited references allegedly teaches (i) the treatment of a period of acute renal failure lasting from only one to three weeks; and (ii) the continuous administration of OP-1 during this one to three week period of acute renal failure.

Rather than specifically pointing out how these two elements are allegedly taught by the combination of references, the Examiner merely alleges that "the differences between the teachings of the references relied upon and the limitations of claims 60-65 would have been obvious absent any evidence that these differences are unexpected and unobvious" (page 3, lines 6-8 of the Office Action dated September 26, 2006). A single circular conclusory statement,

however, is insufficient to satisfy the Examiner's burden of establishing a *prima facie* case of obviousness under MPEP § 706.02(j). The Examiner must specifically point out how all the elements of claim 61, including the two cited above, are allegedly taught by the combination of references, must point out how the references could be combined to achieve the claimed method, and must point out why one skilled in the art would have had a reasonable expectation of success in treating acute renal failure by administering the morphogen only during a period of one to three weeks. Since the Examiner has failed to show meet these three burdens, a *prima facie* case of obviousness has not been made.

CLAIM 64

As indicated in the preceding section, a reasonable expectation of success has not been established for claim 58. Claim 64 is identical to claim 58 except that it further recites "wherein the mammal is afflicted with osteodystrophy." Therefore, the failure to establish a reasonable expectation of success for the method of claim 58 also applies to the method of claim 64, rendering claim 64 also nonobvious.

A failure to establish a *prima facie* case of obviousness also arises from the failure of the Examiner to establish a basis as to how the combination of cited references teaches or suggests the treatment of a subject afflicted with osteodystrophy as recited in claim 64.

The Examiner has not identified any teachings or suggestions in the combination of cited references for treating subjects who are additionally afflicted with osteodystrophy. Instead, the Examiner impermissibly tries to use the specification itself as one of the 103(a) references. The Examiner claims to use "the specification as a dictionary for [the] definition of subjects for treatment" (page 3, lines 20-21 of the Office Action dated September 21, 2006), and concludes that it would have been obvious to treat a subject afflicted with osteodystrophy.

But it is the combination of cited reference, and not the specification of the subject application, that must teach or suggest all the claim elements. This section of the specification states that "[i]n some number of cases, however, the subjects may present with other symptoms (e.g. osteodystrophy) for which morphogen treatment would be indicated." (page 12, lines 5-6). The Examiner cannot use the specification as a reference against itself. The suggestion or

teaching to treat subjects afflicted with osteodystrophy must be found in the prior art. And the section of the specification cited by the Examiner is not providing any type of definition. It is showing embodiments of subjects that may be treated with OP-1.

The Examiner has failed to meet his burden of establishing why treatment of ARF patients additionally afflicted with osteodystrophy is allegedly taught by the prior art, and therefore has failed to make a *prima facie* case of obviousness under MPEP § 706.02(j).

CONCLUSION

In sum, the Examiner has not established a *prima facie* case of obviousness since he failed to show a reasonable expectation of success for using anti-inflammatory morphogens to improve renal function because anti-inflammatory agents were expected to do the opposite: to decrease renal function, i.e., the prior art teaches away from the present invention. Therefore, all independent claims are nonobvious over the cited references, including claims 58, 61 and 64. Furthermore, for claims 61 and 64, the Examiner has failed to show how the cited references teach or suggest all their claim elements.

IX. CLAIMS APPENDIX

A copy of the claims involved in the present appeal is attached hereto as Appendix A. Canceled claims are not shown. No claims are presently allowed.

X. EVIDENCE APPENDIX

No evidence pursuant to §§ 1.130, 1.131, or 1.132 or entered by or relied upon by the Examiner is being submitted.

Application No. 09/445,328
Appeal Brief dated February 9, 2007
After Notice of Appeal dated December 8, 2006

Docket No.: JJJ-P01-514

XI. RELATED PROCEEDINGS APPENDIX

No related proceedings are referenced in II. above, or copies of decisions in related proceedings are not provided, hence no Appendix is included.

XII. CONCLUSIONS

Applicant believes no fee is due other than the \$500 fee for filing an Appeal Brief. However, if an additional fee is due, please charge our Deposit Account No. 18-1945, under Order No. JJJ-P01-514 from which the undersigned is authorized to draw.

Dated: February 9, 2007

Respectfully submitted,

By 
Ignacio Perez de la Cruz
Registration No.: 55,535
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

XIII. Appendix A

Claims Involved in the Appeal of Application Serial No. 09/445,328:

2. A method of effecting an improvement in a standard marker of renal function in a mammal afflicted with acute renal failure, the method comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent comprising a polypeptide comprising a sequence at least 70% homologous to the C terminal seven-cysteine domain of human OP-1, the sequence of the C terminal seven-cysteine domain of human OP-1 being set forth at residues 330-431 of human OP-1, wherein said renal therapeutic agent:
 - (a) induces chondrogenesis in an ectopic bone assay; or
 - (b) prevents, inhibits, delays or alleviates loss of renal function resulting from acute renal failure in an animal model of acute renal failure;
thereby effecting an improvement in a standard marker of renal function in the mammal afflicted with acute renal failure.

53. A method of effecting an improvement in a standard marker of renal function in a mammal afflicted with acute renal failure, the method comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent comprising a polypeptide comprising a sequence at least 60% identical to the C terminal seven-cysteine domain of human OP-1, the sequence of the C terminal seven-cysteine domain of human OP-1 being set forth at residues 330-431 of human OP-1, wherein said renal therapeutic agent:
 - (a) induces chondrogenesis in an ectopic bone assay; or
 - (b) prevents, inhibits, delays or alleviates loss of renal function resulting from acute renal failure in an animal model of acute renal failure;
thereby effecting an improvement in a standard marker of renal function in the mammal afflicted with acute renal failure.

58. A method of effecting an improvement in a standard marker of renal function in a mammal afflicted with acute renal failure, the acute renal failure being one arising from a pre-renal cause of acute renal failure, the method comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent comprising a polypeptide comprising a sequence at least 60% identical or 70% homologous to the C terminal seven-cysteine domain of human OP-1, the sequence of the C terminal seven-cysteine domain of human OP-1 being set forth at residues 330-431 of human OP-1, wherein said renal therapeutic agent:
- (a) induces chondrogenesis in an ectopic bone assay; or
 - (b) prevents, inhibits, delays or alleviates loss of renal function resulting from acute renal failure in an animal model of acute renal failure;
- thereby effecting an improvement in a standard marker of renal function in the mammal afflicted with acute renal failure arising from a pre-renal cause of acute renal failure.
61. A method of effecting an improvement in a standard marker of renal function in a mammal afflicted with acute renal failure, the acute renal failure being one arising from a pre-renal cause of acute renal failure, the method comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent comprising a polypeptide comprising a sequence at least 60% identical or 70% homologous to the C terminal seven-cysteine domain of human OP-1, the sequence of the C terminal seven-cysteine domain of human OP-1 being set forth at residues 330-431 of human OP-1, wherein said renal therapeutic agent:
- (a) induces chondrogenesis in an ectopic bone assay; or
 - (b) prevents, inhibits, delays or alleviates loss of renal function resulting from acute renal failure in an animal model of acute renal failure;
- wherein the agent is administered continuously during the period of acute renal failure, wherein the period of acute renal failure lasts from one to three weeks, thereby effecting an improvement in a standard marker of renal function in the mammal

afflicted with acute renal failure arising from a pre-renal cause of acute renal failure.

64. A method of effecting an improvement in a standard marker of renal function in a mammal afflicted with acute renal failure, the acute renal failure being one arising from a pre-renal cause of acute renal failure, the method comprising administering to said mammal a therapeutically effective amount of an OP/BMP renal therapeutic agent comprising a polypeptide comprising a sequence at least 60% identical or 70% homologous to the C terminal seven-cysteine domain of human OP-1, the sequence of the C terminal seven-cysteine domain of human OP-1 being set forth at residues 330-431 of human OP-1, wherein said renal therapeutic agent:
- (a) induces chondrogenesis in an ectopic bone assay; or
 - (b) prevents, inhibits, delays or alleviates loss of renal function resulting from acute renal failure in an animal model of acute renal failure;
- wherein the mammal is afflicted with osteodystrophy,
thereby effecting an improvement in a standard marker of renal function in the mammal afflicted with acute renal failure arising from a pre-renal cause of acute renal failure.